NCT05546827 is a Phase 2 clinical trial of Surgical resection in Sinonasal Melanoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05546827?

NCT05546827 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05546827?

Interventions in NCT05546827: Surgical resection.

What condition does NCT05546827 study?

NCT05546827 studies Sinonasal Melanoma, Anorectal Melanoma.

Is NCT05546827 still recruiting?

NCT05546827 is currently recruiting now. Last updated 3 March 2026.

Last reviewed 2026-03-03 · How we verify

NCT05546827

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

Recruiting now Phase 2 Last updated 3 March 2026

What this trial tests

Phase 2 trial testing Surgical resection in Sinonasal Melanoma in 40 participants. Currently enrolling.

Timeline

23 September 2022

Primary endpoint
31 July 2028

31 July 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	23 September 2022
Primary completion	31 July 2028
Estimated completion	31 July 2028
Sites	1 location across United States

Drugs / interventions tested

Surgical resection

Conditions studied

Sinonasal Melanoma — all drugs for Sinonasal Melanoma →
Anorectal Melanoma — all drugs for Anorectal Melanoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Sinonasal Melanoma or Anorectal Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Surgical resection

Trials testing the same drug.

NCT06487481 — Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · Phase 1 · recruiting
NCT06908031 — SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer · Phase 2 · recruiting
NCT06504381 — DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma · Phase 1, PHASE2 · recruiting
NCT06575322 — Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depressio · recruiting
NCT06576180 — Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patie · recruiting

Other recruiting trials for Sinonasal Melanoma

Currently open trials in the same condition.

NCT04879654 — Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05546827 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 3 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05546827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing